











22. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory--Second edition: BDI-II-PERSIAN. *Depress Anxiety* 2005; 21(4): 185-92.
23. Farjadian S, Fakhraei B, Moeini M, Nasiri M, Fattahi MR. Serotonin transporter gene polymorphisms in Southwestern Iranian patients with irritable bowel syndrome. *Arab J Gastroenterol* 2013; 14(2): 59-62.
24. Farjadian S, Moghtaderi M, Fakhraei B, Nasiri M, Farjam M. Association between serotonin transporter gene polymorphisms and childhood asthma. *J Asthma* 2013; 50(10): 1031-5.
25. Kaiser R, Muller-Oerlinghausen B, Filler D, Tremblay PB, Berghofer A, Roots I, et al. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. *Am J Med Genet* 2002; 114(3): 323-8.
26. Pytliak M, Vargova V, Mechirova V, Felsoci M. Serotonin receptors - from molecular biology to clinical applications. *Physiol Res* 2011; 60(1): 15-25.
27. Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. *Mol Interv* 2004; 4(2): 109-23.
28. Nemeroff CB, Owens MJ. The role of serotonin in the pathophysiology of depression: as important as ever. *Clin Chem* 2009; 55(8): 1578-9.
29. Starr LR, Hammen C, Brennan PA, Najman JM. Relational security moderates the effect of serotonin transporter gene polymorphism (5-HTTLPR) on stress generation and depression among adolescents. *J Abnorm Child Psychol* 2013; 41(3): 379-88.
30. Saul A, Taylor B, Simpson S Jr, Ponsonby AL, Blizzard L, Dwyer T, et al. Polymorphism in the serotonin transporter gene polymorphisms (5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis. *Mult Scler* 2018. [Epub ahead of print].
31. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. *Altern Med Rev* 2008; 13(3): 216-26.
32. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* 2010; 464(7285): 104-7.
33. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. *Nat Rev Neurol* 2014; 10(4): 225-38.
34. Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: A systematic review. *BMC Neurol* 2013; 13: 128.
35. Farjam M, Ebrahimpour A, Fakhraei B. CD21 positive B cell: A novel target for treatment of multiple sclerosis. *Med Hypotheses* 2013; 80(5): 556-7.
36. Vojdani A. A potential link between environmental triggers and autoimmunity. *Autoimmune Diseases* 2014; 2014: 437231.
37. Kucukali CI, Kurtuncu M, Coban A, Cebi M, Tuzun E. Epigenetics of multiple sclerosis: An updated review. *Neuro Molecular Med* 2015; 17(2): 83-96.
38. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. *Prog Neuropsychopharmacol Biol Psychiatry* 2013; 45: 54-63.

Proof Version